Loading clinical trials...
Loading clinical trials...
This is an open label trial of the NMDA agonist glycine used alone for symptoms that appear to be prodromal for schizophrenia in adolescents and young adults.
Keep your clinical trial research organized — questions to ask, what to expect, and key details.
Lead Sponsor
Yale University
Collaborators
NCT06894212 · Schizophrenia
NCT06003036 · Schizophrenia, Schizoaffective Disorder
NCT04226898 · Schizophrenia, Schizoaffective Disorder
NCT05052853 · Prodromal Schizophrenia
NCT05240976 · Schizophrenia
Use Clareo to keep notes, questions, trial details, and next steps organized before and after appointments.
Start free trial →Data Source & Attribution
This clinical trial information is sourced from ClinicalTrials.gov, a service of the U.S. National Institutes of Health.
Modifications: This data has been reformatted for display purposes. Eligibility criteria have been parsed into inclusion/exclusion sections. Location data has been geocoded to enable distance-based search. For the authoritative and most current information, please visit ClinicalTrials.gov.
Neither the United States Government nor Clareo Health make any warranties regarding the data. Check ClinicalTrials.gov frequently for updates.
View ClinicalTrials.gov Terms and Conditions